Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe ...

AbbVie became a stand-alone company in 2012 after it split from its former parent company, Abbott Laboratories. Since then, it has increased its payouts by an impressive 288%. When including the ...

DelveInsight's Hormone Replacement Therapy Market Insights report provides the current and forecast market analysis, ...

Abbott and AbbVie also increased their market cap by more than 50% in 2017, supported by their promising late-stage clinical pipelines. For AbbVie this includes its oral JAK1-selective inhibitor ...

The hormone replacement therapy market is witnessing substantial growth due to the rising occurrence of hormonal and targeted conditions such as menopause and osteoporosis, coupled with the ...

Abbott Laboratories has petitioned the Internal Revenue Service in federal tax court for a $24.3 million tax refund and a redetermination of numerous IRS-claimed deficiencies in its federal income ...

AbbVie plans to present the full results at medical conferences and expects additional trial data from TEMPO-2 by the end of 2024. Tavapadon is an investigational D1/D5 dopamine receptor partial ...